DCE-MRI can also differentiate between trastuzumab-responsive and trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer xenografts, providing valuable insights into mechanisms of treatment resistance [58]. Here, ERBB2 is linked to breast carcinoma.